Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth.

Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J.

Nature. 1990 Dec 6;348(6301):555-7.

PMID:
1701033
2.

Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent.

Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J.

Biochem Biophys Res Commun. 1991 Feb 14;174(3):1070-6.

PMID:
1705118
3.

Synthesis and biological evaluation of novel fumagillin and ovalicin analogues.

Mazitschek R, Huwe A, Giannis A.

Org Biomol Chem. 2005 Jun 7;3(11):2150-4. Epub 2005 Apr 22.

PMID:
15917904
4.

Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin.

Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, Biemann K, Liu JO.

Chem Biol. 1997 Jun;4(6):461-71.

PMID:
9224570
5.

Fumagillin inhibits colorectal cancer growth and metastasis in mice: in vivo and in vitro study of anti-angiogenesis.

Hou L, Mori D, Takase Y, Meihua P, Kai K, Tokunaga O.

Pathol Int. 2009 Jul;59(7):448-61. doi: 10.1111/j.1440-1827.2009.02393.x.

PMID:
19563408
6.

Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats.

Stepień H, Grochal M, Zieliński KW, Mucha S, Kunert-Radek J, Kulig A, Stawowy A, Pisarek H.

J Endocrinol. 1996 Jul;150(1):99-106.

PMID:
8708569
7.

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.

Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM.

Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6099-103.

8.

[On chance discovery in rational drug design. Aspergillus fumigatus and angiogenesis].

Klein C.

Pharm Unserer Zeit. 2007;36(6):450-1. Review. German.

PMID:
17957690
9.

Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2.

Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO.

Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15183-8.

10.

Aspergillus, angiogenesis, and obesity: the story behind beloranib.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2015 Mar;53(3):13-6. doi: 10.3928/02793695-20150219-01. Review.

PMID:
25751824
11.

Fumagillin: an overview of recent scientific advances and their significance for apiculture.

van den Heever JP, Thompson TS, Curtis JM, Ibrahim A, Pernal SF.

J Agric Food Chem. 2014 Apr 2;62(13):2728-37. doi: 10.1021/jf4055374. Epub 2014 Mar 21. Review.

PMID:
24621007
12.

Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors.

Lefkove B, Govindarajan B, Arbiser JL.

Expert Rev Anti Infect Ther. 2007 Aug;5(4):573-9. Review.

PMID:
17678422
13.

Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.

Lu J, Chong CR, Hu X, Liu JO.

J Med Chem. 2006 Sep 21;49(19):5645-8.

PMID:
16970390
14.

Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia.

Nishimura Y, Murata R, Hiraoka M.

Br J Cancer. 1996 Feb;73(3):270-4.

15.

Inhibitory effects of 9-(4-thio-beta-D-ribo-pentofuranosyl)guanine on tumor growth and angiogenesis.

Miura S, Yamada K, Kano F, Yoshimura Y.

Biol Pharm Bull. 2004 Apr;27(4):520-3.

16.

A re-evaluation of fumagillin selectivity towards endothelial cells.

Rodriguez-Nieto S, Medina MA, Quesada AR.

Anticancer Res. 2001 Sep-Oct;21(5):3457-60.

PMID:
11848509
17.

Anti-angiogenic activity of arachidonic acid metabolism inhibitors in angiogenesis model systems involving human microvascular endothelial cells and neovascularization in mice.

Ito K, Abe T, Tomita M, Morimoto A, Kohno K, Mori T, Ono M, Sugenoya A, Nishihira T, Kuwano M.

Int J Cancer. 1993 Oct 21;55(4):660-6.

PMID:
7691764
18.

Design, synthesis, and antiangiogenic effects of a series of potent novel fumagillin analogues.

Lee HW, Cho CS, Kang SK, Yoo YS, Shin JS, Ahn SK.

Chem Pharm Bull (Tokyo). 2007 Jul;55(7):1024-9.

19.

Novel bicyclic oxazolone derivatives as anti-angiogenic agents.

Perron-Sierra FM, Pierré A, Burbridge M, Guilbaud N.

Bioorg Med Chem Lett. 2002 Jun 3;12(11):1463-6.

PMID:
12031320
20.

Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2.

Han CK, Ahn SK, Choi NS, Hong RK, Moon SK, Chun HS, Lee SJ, Kim JW, Hong CI, Kim D, Yoon JH, No KT.

Bioorg Med Chem Lett. 2000 Jan 3;10(1):39-43.

PMID:
10636239

Supplemental Content

Support Center